紀由屋分享坊
Would you like to react to this message? Create an account in a few clicks or log in to continue.

公告:
紀由屋分享坊將於近日進行大規模更新,期間排版及貼文內容可能有所變動,敬請見諒。
kikyus.net will undergo a major update soon. During this period, changes in layout and post content may occur. Please bear with us.
生成工具:

amayrashah15
amayrashah15
屋友
Online
Offline

文章數 : 87
紀由幣 : 0
注冊日期 : 2023-04-03

Fetal Bovine Serum Market To experience steady growth during 2022-2028 Empty Fetal Bovine Serum Market To experience steady growth during 2022-2028

周一 4月 03, 2023 6:06 pm
The fetal bovine serum (FBS) market refers to the industry that produces and distributes FBS, a blood product derived from fetal bovine (cow) blood. FBS is a common supplement used in cell culture to provide nutrients and growth factors necessary for the growth and maintenance of cells. FBS is used in a wide range of applications, including the development of vaccines, biopharmaceuticals, and cell-based therapies. The FBS market includes manufacturers, distributors, and end-users who require FBS for their research or production processes. The market is influenced by factors such as demand for cell-based products, advancements in cell culture technology, and ethical considerations related to the use of animal-derived products. The fetal bovine serum market was estimated at US$ 874.1 million in 2021 and is expected to grow at a CAGR of 5.18% during 2022-2028 to reach US$ ~1.19 billion in 2028.
Fetal bovine serum is a key component in the production of cell-based products such as vaccines, cell therapies, and biopharmaceuticals. The FBS market has experienced steady growth in recent years due to increasing demand for these cell-based products in both research and clinical settings.
However, there are concerns regarding the ethical and environmental implications of using FBS, which is sourced from fetal bovine blood. As a result, there is growing interest in developing alternative, animal-free serum supplements.
One potential future outlook for the FBS market is increased regulation and scrutiny regarding the ethical and environmental implications of its use. This could lead to a shift towards alternative serum supplements or the development of more sustainable and ethical practices for sourcing FBS.
Another possibility is continued growth of the FBS market as demand for cell-based products continues to increase, particularly in the fields of regenerative medicine and personalized medicine. In this scenario, there may be a greater focus on ensuring the quality and consistency of FBS products, as well as exploring new applications and uses for FBS.
Overall, the future outlook for the FBS market will depend on a variety of factors, including ethical considerations, technological advancements, and market demand for cell-based products.
Request a sample here:
https://www.stratviewresearch.com/Request-Sample/3158/fetal-bovine-serum-market.html#form
North America and Europe are currently the two major markets for foetal bovine serum, and they are likely to account for a higher share of the market during the forecast period. This is because these regions have large populations of bovine and cattle to permit the production of foetal bovine serum, as well as a high share of R&D activities. Because of its vast cattle population and favourable government backing for research and development, Australia is likely to present the largest market opportunity in Asia Pacific.
The overall competitive landscape has been affected due to the key strategic activities. The following are the major players in the fetal bovine serum market:
• HiMedia Laboratories
• Merck KGaA
• Bovogen Biologicals Pty Ltd
• Atlanta Biologicals Inc.
• TCS Biosciences Ltd
• Tissue Culture Biologicals
• Rocky Mountain Biologicals
• GE Healthcare
• Thermo Fisher Scientific
• Bio-Techne
• PAN-Biotech
• Access Biologicals
The fetal bovine serum (FBS) market is expected to continue to grow in the coming years due to increasing demand for cell-based products in various industries, including biopharmaceuticals, regenerative medicine, and personalized medicine. However, there are concerns about the ethical and environmental implications of using FBS, which could lead to a shift towards alternative, animal-free serum supplements.
To address these concerns, some companies are exploring new methods for sourcing FBS that are more sustainable and ethical. Additionally, advancements in cell culture technology may lead to the development of new serum-free media formulations that can replace FBS entirely.
Overall, the future prospects of the FBS market will depend on a variety of factors, including ethical considerations, technological advancements, and market demand for cell-based products. The industry will need to adapt to changing market conditions and consumer preferences to remain competitive and sustainable in the long term.


查看下一個下一個上一篇主題查看上一個
這個論壇的權限:
無法 在這個版面回復文章